文献速递腹部技术与安全CT

纵向CT影像组学预测局部进展期胃癌新辅助化疗后无进展生存期

Longitudinal CT Radiomics to Predict Progression-free Survival in Patients with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy.
PubMed 文献 · Acad Radiol · 2024-12-27

本研究回顾性纳入316例接受新辅助化疗后胃切除术的局部进展期胃癌患者,基于基线和再分期静脉期CT提取影像组学特征构建四种影像组学标签,并将多时间点影像组学标签与临床因素结合建立列线图模型。该影像组学-临床模型在训练组和验证组的C-index分别为0.754和0.719,能准确将患者分为三个无进展生存风险组。

要点

  • 多时间点影像组学标签(PrePost-Rad)在验证组C-index为0.724,优于基线、再分期和delta标签。
  • 影像组学-临床模型预测无进展生存的C-index在训练组为0.754,验证组为0.719。
  • 影像组学-临床模型可将新辅助化疗后胃癌患者分为三个无进展生存风险组。

核心结论

  • 整合纵向影像组学评分和临床因素的影像组学-临床模型在术前预测局部进展期胃癌患者新辅助化疗及手术后的无进展生存方面表现良好。

研究设计与样本

  • 单中心回顾性研究,共纳入316例接受新辅助化疗后胃切除术的局部进展期胃癌患者,按医院不同区域分为训练组(n=243)和验证组(n=73);从静脉期CT图像感兴趣区提取1316个影像组学特征。

诊断标准与关键数值

  • 基于基线CT的影像组学标签(Pre-Rad)在验证组预测无进展生存的C-index为0.715(95% CI:0.632-0.798)。
  • 基于再分期CT的影像组学标签(Post-Rad)在验证组预测无进展生存的C-index为0.632(95% CI:0.538-0.725)。
  • delta影像组学标签(Delta-Rad)在验证组预测无进展生存的C-index为0.549(95% CI:0.447-0.651)。
  • 多时间点影像组学标签(PrePost-Rad)在验证组预测无进展生存的C-index为0.724(95% CI:0.639-0.809)。
  • 影像组学-临床模型预测无进展生存的C-index在训练组为0.754(95% CI:0.707-0.800),在验证组为0.719(95% CI:0.639-0.800)。

临床应用与阅片要点

  • 作者构建的影像组学-临床模型可术前预测局部进展期胃癌患者新辅助化疗后的无进展生存,并可将患者分为三个风险组。
  • 风险分层在大多数亚组中表现良好,包括良好反应者、不良反应者、ypTNM Ⅱ期和ypTNM Ⅲ/Ⅳ期。

局限性

  • 本研究为单中心回顾性研究。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

RATIONALE AND OBJECTIVES: To develop and validate a radiomics signature, utilizing baseline and restaging CT, for preoperatively predicting progression-free survival (PFS) after neoadjuvant chemotherapy (NAC) in locally advanced gastric cancer (LAGC).

METHODS: A total of 316 patients with LAGC who received NAC followed by gastrectomy were retrospectively included in this single-center study; these patients were split into two cohorts, one for training (n = 243) and the other for validation (n = 73), based on the different districts of our hospital. A total of 1316 radiomics features were extracted from the volume of interest of the gastric-cancer lesion on venous phase CT images. Four radiomics signatures were built for predicting PFS based on baseline CT (Pre-Rad), restaging CT (Post-Rad), delta radiomics (Delta-Rad) and multi-time radiomics (PrePost-Rad), respectively. Then the PrePost-Rad was combined with clinical factors to establish a nomogram (Rad-clinical model). Kaplan-Meier survival curves with log-rank tests were used to assess the prognostic usefulness of the Rad-clinical model.

RESULTS: All baseline characteristics were not statistically different between the two cohorts. The PrePost-Rad achieved improved predictive value by a C-index of 0.724 (95% CI: 0.639-0.809) in the validation cohort [Pre-Rad: 0.715 (0.632-0.798); Post-Rad: 0.632 (0.538-0.725), Delta-Rad: 0.549 (0.447-0.651)]. In terms of clinical benefit, calibration capability, and prediction efficacy, the Rad-clinical model performed well for PFS prediction, with a C-index of 0.754 (95% CI: 0.707-0.800) and 0.719 (95% CI: 0.639-0.800) in the training and validation cohorts, respectively, superior to the clinical model (cN stage and CA199) but comparable to the PrePost-Rad. Moreover, the Rad-clinical model could accurately classify gastric-cancer patients after NAC into three PFS risk groups in both training and validation cohorts. The risk stratification also performed well in most subgroups (good responders, poor responders, ypTNM Ⅱ, and ypTNM Ⅲ/Ⅳ).

CONCLUSIONS: The Rad-clinical model integrating longitudinal radiomics score and clinical factors performed well in preoperatively predicting PFS of LAGC patients after NAC and surgery.

来源:Acad Radiol,查看原文。版权归原作者所有。

引用

  1. Wang B, Han X, Zhang Z, et al. Longitudinal CT Radiomics to Predict Progression-free Survival in Patients with Locally Advanced Gastric Cancer After Neoadjuvant Chemotherapy. Acad Radiol. 2024. PMID: 39732617. doi:10.1016/j.acra.2024.11.068

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。